The growth of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the early sales data were impressive, the exclusivity has expired, leading to a wave of copycat alternatives https://arunxoui997189.bloginder.com/42010967/the-blue-pill-and-big-pharma-a-dangerous-opportunity